Childhood acute lymphoblastic leukemia (ALL) is a heterogeneous group of diseases. The major challenge in the treatment of childhood ALL is to save patients who have relapsed despite intensive multiagent chemotherapy. Among all age groups, CD19 antigen positive G-lineage ALL is the most prevalent ALL. Our proposal is designed to generate valuable information regarding (a) the biologic heterogeneity of newly diagnosed B-lineage ALL, and (b) the ability of novel combinative therapy regimens to reduce or eradicate the leukemia burden of relapsed B-lineage patients. A first major goal of this proposal is to determine the prognostic value of ALL blast clonogenicity in SCID mice for children with newly diagnosed ALL (SPECIFIC AIM 1). It is our central working hypothesis that blast clonogenicity in SCID mice is a powerful and independent predictor of relapse after chemotherapy. A second major goal is to measure the quality of second remission in relapsed B-lineage ALL patients after reinduction and intensification regimens using quantitative minimal residual leukemia detection assay system developed in our laboratory (SPECIFIC AIM 2). The major hypotheses to be tested under SPECIFIC AIM 2 are 1. In patients who do not undergo BMT, the quality of remission after reinduction, i.e., the residual LPC burden of Pre-BMT bone marrow will be a strong predictor of outcome.
Under SPECIFIC AIM 3, we will examine the impact of B43-PAP anti-CD19 immunotoxin therapy on the quality of second remission in relapsed B- lineage ALL patients. Our hypothesis is that the combination of chemotherapy with B43-PAP will prove more effective than chemotherapy alone in reducing or eradicating the residual LPC burden of relapsed ALL patients and will improve the event-free survival rate. We anticipate that the studies proposed under SPECIFIC AIMS 1-3 will allow us to accurately segregate B-lineage ALL patients into distinct prognostic groups both at the time of diagnosis as well as after induction of remission. The knowledge gained from our research may lead to the design of more successful treatment strategies for relapsed B-lineage ALL.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01CA060437-03
Application #
2101186
Study Section
Special Emphasis Panel (SRC (51))
Project Start
1993-09-01
Project End
1997-06-30
Budget Start
1995-07-01
Budget End
1996-06-30
Support Year
3
Fiscal Year
1995
Total Cost
Indirect Cost
Name
National Childhood Cancer Foundation
Department
Type
DUNS #
624124301
City
Arcadia
State
CA
Country
United States
Zip Code
91006
Sweetser, David A; Peniket, Andrew J; Haaland, Christina et al. (2005) Delineation of the minimal commonly deleted segment and identification of candidate tumor-suppressor genes in del(9q) acute myeloid leukemia. Genes Chromosomes Cancer 44:279-91
Heerema, N A; Nachman, J B; Sather, H N et al. (2004) Deletion of 7p or monosomy 7 in pediatric acute lymphoblastic leukemia is an adverse prognostic factor: a report from the Children's Cancer Group. Leukemia 18:939-47
Levy, Adam S; Sather, Harland N; Steinherz, Peter G et al. (2003) Reduced folate carrier and dihydrofolate reductase expression in acute lymphocytic leukemia may predict outcome: a Children's Cancer Group Study. J Pediatr Hematol Oncol 25:688-95
Heerema, Nyla A; Sather, Harland N; Sensel, Martha G et al. (2002) Abnormalities of chromosome bands 15q13-15 in childhood acute lymphoblastic leukemia. Cancer 94:1102-10
Sweetser, D A; Chen, C S; Blomberg, A A et al. (2001) Loss of heterozygosity in childhood de novo acute myelogenous leukemia. Blood 98:1188-94
Gaynon, P S; Bostrom, B C; Hutchinson, R J et al. (2001) Duration of hospitalization as a measure of cost on Children's Cancer Group acute lymphoblastic leukemia studies. J Clin Oncol 19:1916-25
Heerema, N A; Sather, H N; Sensel, M G et al. (2000) Prognostic impact of trisomies of chromosomes 10, 17, and 5 among children with acute lymphoblastic leukemia and high hyperdiploidy (> 50 chromosomes). J Clin Oncol 18:1876-87
Heerema, N A; Sather, H N; Sensel, M G et al. (2000) Prognostic significance of cytogenetic abnormalities of chromosome arm 12p in childhood acute lymphoblastic leukemia: a report from the Children's Cancer Group. Cancer 88:1945-54
Heerema, N A; Sather, H N; Sensel, M G et al. (2000) Clinical significance of deletions of chromosome arm 6q in childhood acute lymphoblastic leukemia: a report from the Children's Cancer Group. Leuk Lymphoma 36:467-78
Heerema, N A; Sather, H N; Sensel, M G et al. (2000) Abnormalities of chromosome bands 13q12 to 13q14 in childhood acute lymphoblastic leukemia. J Clin Oncol 18:3837-44

Showing the most recent 10 out of 25 publications